Media stories about Seres Therapeutics (NASDAQ:MCRB) have trended somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Seres Therapeutics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.2308358864881 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
- Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader (marketwatch.com)
- Are Traders Shorting Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares? (vassarnews.com)
- Seres Therapeutics, Inc. (NasdaqGS:MCRB)’s Net Profit Growth of -0.06013 Is Turning Heads (vassarnews.com)
- Up to Date Stocks in Review: GoPro, Inc. (NASDAQ:GPRO), Seres Therapeutics, Inc. (NASDAQ:MCRB), iCAD, Inc … (journalfinance.net)
A number of research firms have weighed in on MCRB. BidaskClub upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 7th. ValuEngine lowered Seres Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 30th. Zacks Investment Research upgraded Seres Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a report on Wednesday, May 16th. Finally, Bank of America lowered Seres Therapeutics from a “neutral” rating to an “underperform” rating in a report on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $17.25.
Shares of MCRB stock traded up $0.25 during trading hours on Wednesday, reaching $8.91. 4,725 shares of the company’s stock were exchanged, compared to its average volume of 83,183. The company has a market cap of $358.19 million, a PE ratio of -4.03 and a beta of 0.53. The company has a current ratio of 2.76, a quick ratio of 2.76 and a debt-to-equity ratio of -0.61. Seres Therapeutics has a fifty-two week low of $6.65 and a fifty-two week high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. The business had revenue of $4.61 million for the quarter, compared to the consensus estimate of $5.22 million. Seres Therapeutics had a negative return on equity of 256.24% and a negative net margin of 264.31%. equities analysts forecast that Seres Therapeutics will post -2.45 earnings per share for the current year.
In other news, CEO Roger Pomerantz sold 40,057 shares of the company’s stock in a transaction on Friday, June 22nd. The stock was sold at an average price of $9.36, for a total transaction of $374,933.52. Following the transaction, the chief executive officer now directly owns 297,812 shares of the company’s stock, valued at $2,787,520.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John G. Aunins sold 14,279 shares of the company’s stock in a transaction on Friday, June 15th. The stock was sold at an average price of $8.57, for a total value of $122,371.03. Following the transaction, the insider now directly owns 170,206 shares in the company, valued at $1,458,665.42. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 191,048 shares of company stock worth $1,736,213. Insiders own 37.10% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
Further Reading: What is a Stop Order?
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.